Literature DB >> 11383716

Effects of Ro 64-6198 in nociceptin/orphanin FQ-sensitive isolated tissues.

D Rizzi1, R Bigoni, A Rizzi, F Jenck, J Wichmann, R Guerrini, D Regoli, G Calo.   

Abstract

The pharmacological profile of the non-peptide OP4 receptor (ORL1, LC132) agonist, Ro 64-6198, was investigated, in three electrically stimulated nociceptin/orphanin FQ (NC)-sensitive preparations, namely the mouse and rat vas deferens and the guinea pig ileum. Ro 64-6198 mimicked the inhibitory effect of NC in the three preparations, while showing slow kinetics of action and a slowly reversible effect compared to the fast and immediately and completely reversible effect of the natural peptide. Ro 64-6198 displayed similar pEC50 and Emax values as NC in the mouse and rat vas deferens while it was 100-fold less potent but more efficacious (higher Emax) than NC in the guinea pig ileum. In the rat vas deferens the effects of Ro 64-6198 were antagonised by [Nphe1]NC(1-13)NH2 and J-113397 with pKB values (6.30 and 8.05, respectively) similar to those obtained against NC (6.20 and 7.77, respectively). Naloxone (1 microM) was inactive. In the guinea pig ileum a clear shift of the concentration response curve to Ro 64-6198 was obtained only using a cocktail of antagonists (naloxone + [Nphe1]NC(1-13)NH2 or naloxone + J-113397). In the mouse vas deferens the antagonists were inactive against Ro 64-6198 either when tested alone or in combination. Therefore, Ro 64-6198 behaved as a selective OP4 receptor agonist only in the rat tissue. These results suggest a physiological heterogeneity in OP4 receptors across tissues and species and may explain why, when tested in vivo, Ro 64-6198 mimics the potent anxiolytic effect of NC better in the rat than in the mouse.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11383716     DOI: 10.1007/s002100100399

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  15 in total

Review 1.  Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Authors:  Nurulain T Zaveri
Journal:  J Med Chem       Date:  2016-03-14       Impact factor: 7.446

2.  In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives.

Authors:  A Rizzi; D Malfacini; M C Cerlesi; C Ruzza; E Marzola; M F Bird; D J Rowbotham; S Salvadori; R Guerrini; D G Lambert; G Calo
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

3.  In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.

Authors:  Federica Ferrari; Maria Camilla Cerlesi; Davide Malfacini; Laila Asth; Elaine C Gavioli; Blair V Journigan; Uma Gayathri Kamakolanu; Michael E Meyer; Dennis Yasuda; Willma E Polgar; Anna Rizzi; Remo Guerrini; Chiara Ruzza; Nurulain T Zaveri; Girolamo Calo
Journal:  Eur J Pharmacol       Date:  2016-10-22       Impact factor: 4.432

Review 4.  UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.

Authors:  Girolamo Calo'; Anna Rizzi; Carlo Cifani; Maria Vittoria Micioni Di Bonaventura; Domenico Regoli; Maurizio Massi; Severo Salvadori; David G Lambert; Remo Guerrini
Journal:  CNS Neurosci Ther       Date:  2010-05-18       Impact factor: 5.243

5.  Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice.

Authors:  Anna Rizzi; Daniela Rizzi; Giuliano Marzola; Domenico Regoli; Bjarne Due Larsen; Jorgen Soberg Petersen; Girolamo Calo'
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

Review 6.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

7.  The smooth muscle relaxant effect of hydrogen sulphide in vitro: evidence for a physiological role to control intestinal contractility.

Authors:  B Teague; S Asiedu; P K Moore
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

8.  Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein G alpha qi5.

Authors:  Valeria Camarda; Carmela Fischetti; Nicholas Anzellotti; Paola Molinari; Caterina Ambrosio; Evi Kostenis; Domenico Regoli; Claudio Trapella; Remo Guerrini; Salvadori Severo; Girolamo Calo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-01-28       Impact factor: 3.000

9.  Evidence in locomotion test for the functional heterogeneity of ORL-1 receptors.

Authors:  Alexander Kuzmin; Johan Sandin; Lars Terenius; Sven Ove Ogren
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

Review 10.  Cellular mechanisms of nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor regulation and heterologous regulation by N/OFQ.

Authors:  Courtney L Donica; Hibah O Awwad; Deepak R Thakker; Kelly M Standifer
Journal:  Mol Pharmacol       Date:  2013-02-08       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.